Literature DB >> 20403309

Rift Valley fever--a threat for Europe?

V Chevalier1, M Pépin, L Plée, R Lancelot.   

Abstract

Rift Valley fever (RVF) is a severe mosquito-borne disease affecting humans and domestic ruminants, caused by a Phlebovirus (Bunyaviridae). It is widespread in Africa and has recently spread to Yemen and Saudi Arabia. RVF epidemics are more and more frequent in Africa and the Middle East, probably in relation with climatic changes (episodes of heavy rainfall in eastern and southern Africa), as well as intensified livestock trade. The probability of introduction and large-scale spread of RVF in Europe is very low, but localized RVF outbreaks may occur in humid areas with a large population of ruminants. Should this happen, human cases would probably occur in exposed individuals: farmers, veterinarians, slaughterhouse employees etc. Surveillance and diagnostic methods are available, but control tools are limited: vector control is difficult to implement, and vaccines are only available for ruminants, with either a limited efficacy (inactivated vaccines) or a residual pathogenic effect. The best strategy to protect Europe and the rest of the world against RVF is to develop more efficient surveillance and control tools and to implement coordinated regional monitoring and control programmes.

Entities:  

Mesh:

Year:  2010        PMID: 20403309

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  78 in total

Review 1.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

Review 2.  Incubation periods of mosquito-borne viral infections: a systematic review.

Authors:  Kara E Rudolph; Justin Lessler; Rachael M Moloney; Brittany Kmush; Derek A T Cummings
Journal:  Am J Trop Med Hyg       Date:  2014-03-17       Impact factor: 2.345

3.  Ultrastructural pathology of human liver in Rift Valley fever.

Authors:  Mubarak Al Shraim; Refaat Eid; Khaled Radad; Noora Saeed
Journal:  BMJ Case Rep       Date:  2016-08-02

4.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Coupling Vector-host Dynamics with Weather Geography and Mitigation Measures to Model Rift Valley Fever in Africa.

Authors:  B H McMahon; C A Manore; J M Hyman; M X LaBute; J M Fair
Journal:  Math Model Nat Phenom       Date:  2014-01-01       Impact factor: 4.157

6.  Environmental limits of Rift Valley fever revealed using ecoepidemiological mechanistic models.

Authors:  Giovanni Lo Iacono; Andrew A Cunningham; Bernard Bett; Delia Grace; David W Redding; James L N Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-18       Impact factor: 11.205

7.  Seroprevalence of Rift Valley fever virus infection in camels (dromedaries) in northern Tanzania.

Authors:  Emmanuel Senyael Swai; Calvin Sindato
Journal:  Trop Anim Health Prod       Date:  2014-11-29       Impact factor: 1.559

8.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

9.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

10.  Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.

Authors:  Elizabeth R Wonderlich; Amy L Caroline; Cynthia M McMillen; Aaron W Walters; Douglas S Reed; Simon M Barratt-Boyes; Amy L Hartman
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.